Literature DB >> 25486959

Biology and treatment of myeloma.

Annamaria Brioli1, Lorenzo Melchor2, Brian A Walker2, Faith E Davies2, Gareth J Morgan3.   

Abstract

In recent years significant progress has been made in the understanding of multiple myeloma (MM) biology and its treatment. Current strategies for the treatment of MM involve the concept of sequential blocks of therapy given as an induction followed by consolidation and maintenance. In an age characterized by emerging and more powerful laboratory techniques, it is of primary importance to understand the biology of MM and how this biology can guide the development of new treatment strategies. This review focuses on the genetic basis of myeloma, including the most common genetic abnormalities and pathways affected and the effects that these have on MM treatment strategies. MM biology is discussed also in the light of more recent theory of intraclonal heterogeneity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetic; Intraclonal heterogeneity; Multiple myeloma; Sequential treatment; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25486959     DOI: 10.1016/j.clml.2014.06.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  9 in total

1.  Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models.

Authors:  Enrica Borsi; Marina Martello; Barbara Santacroce; Elena Zamagni; Paola Tacchetti; Lucia Pantani; Katia Mancuso; Serena Rocchi; Michele Cavo; Carolina Terragna
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

2.  Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Authors:  Denise K Walters; Bonnie K Arendt; Renee C Tschumper; Xiaosheng Wu; Diane F Jelinek
Journal:  Exp Hematol       Date:  2017-10-13       Impact factor: 3.084

3.  MMSA-1 expression pattern in multiple myeloma and its clinical significance.

Authors:  Shan Meng; Chenyang Lu; Wanggang Zhang; Wenjun Shen; Yongchang Wei; Dan Su; Fuling Zhou
Journal:  Clin Exp Med       Date:  2015-10-22       Impact factor: 3.984

4.  Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.

Authors:  Charlotte Fristedt Duvefelt; Susanne Lub; Prasoon Agarwal; Linda Arngården; Anna Hammarberg; Ken Maes; Els Van Valckenborgh; Karin Vanderkerken; Helena Jernberg Wiklund
Journal:  Oncotarget       Date:  2015-08-21

5.  Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Authors:  Prasoon Agarwal; Mohammad Alzrigat; Alba Atienza Párraga; Stefan Enroth; Umashankar Singh; Johanna Ungerstedt; Anders Österborg; Peter J Brown; Anqi Ma; Jian Jin; Kenneth Nilsson; Fredrik Öberg; Antonia Kalushkova; Helena Jernberg-Wiklund
Journal:  Oncotarget       Date:  2016-02-09

6.  Mitochondrial DNA plasticity is an essential inducer of tumorigenesis.

Authors:  W T Y Lee; J E Cain; A Cuddihy; J Johnson; A Dickinson; K-Y Yeung; B Kumar; T G Johns; D N Watkins; A Spencer; J C St John
Journal:  Cell Death Discov       Date:  2016-04-04

Review 7.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 8.  Molecular mechanisms in multiple myeloma drug resistance.

Authors:  Nicholas Nikesitch; Silvia C W Ling
Journal:  J Clin Pathol       Date:  2015-11-23       Impact factor: 3.411

9.  c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Authors:  Alessandra Di Bacco; Nizar J Bahlis; Nikhil C Munshi; Hervé Avet-Loiseau; Tamás Masszi; Luísa Viterbo; Ludek Pour; Peter Ganly; Michele Cavo; Christian Langer; Shaji K Kumar; S Vincent Rajkumar; Jonathan J Keats; Deborah Berg; Jianchang Lin; Bin Li; Sunita Badola; Lei Shen; Jacob Zhang; Dixie-Lee Esseltine; Katarina Luptakova; Helgi van de Velde; Paul G Richardson; Philippe Moreau
Journal:  Eur J Haematol       Date:  2020-04-15       Impact factor: 2.997

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.